Read this text module to learn the latest information about Tcellengaging therapies targeting DLL3 in extensivestage smallcell lung cancer ESSCLC
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/targeting-dll3-in-es-sclc-1/31344-60566
- Start Date: 2024-11-07 06:00:00
- End Date: 2024-11-07 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Boehringer Ingelheim Pharmaceuticals, Inc. - Amount: 50000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest